---
title: "Regeneron Pharmaceuticals, Inc. (REGN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/REGN.US.md"
symbol: "REGN.US"
name: "Regeneron Pharmaceuticals, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T13:00:06.227Z"
locales:
  - [en](https://longbridge.com/en/quote/REGN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/REGN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/REGN.US.md)
---

# Regeneron Pharmaceuticals, Inc. (REGN.US)

## Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.regeneron.com](https://www.regeneron.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:14.000Z

**Overall: B (0.38)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 8 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 5.92% |  |
| Net Profit YoY | -1.69% |  |
| P/B Ratio | 2.12 |  |
| Dividend Ratio | 0.57% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 66569647442.08 |  |
| Revenue | 14919600000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 14.55% | B |
| Profit Margin | 29.65% | A |
| Gross Margin | 38.62% | B |
| Revenue YoY | 5.92% | C |
| Net Profit YoY | -1.69% | C |
| Total Assets YoY | 8.85% | B |
| Net Assets YoY | 6.93% | B |
| Cash Flow Margin | 113.32% | C |
| OCF YoY | 5.92% | C |
| Turnover | 0.38 | C |
| Gearing Ratio | 23.11% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Regeneron Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "5.92%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-1.69%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.12",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.57%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "66569647442.08",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "14919600000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "14.55%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "29.65%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "38.62%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "5.92%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-1.69%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "8.85%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "6.93%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "113.32%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "5.92%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.38",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "23.11%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 15.05 | 30/386 | 17.58 | 15.54 | 13.11 |
| PB | 2.12 | 198/386 | 2.56 | 2.30 | 1.97 |
| PS (TTM) | 4.46 | 98/386 | 5.57 | 4.95 | 4.13 |
| Dividend Yield | 0.57% | 8/386 | 0.47% | 0.46% | 0.34% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **29**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 16 | 55% |
| Overweight | 4 | 14% |
| Hold | 9 | 31% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 629.68 |
| Highest Target | 1057.00 |
| Lowest Target | 730.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/REGN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/REGN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/REGN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/REGN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**